New pharmacological targets against COVID-19: the use of interferons for activating the antiviral state and eliminating the SARC-CoV-2 virus
DOI:
https://doi.org/10.33448/rsd-v10i11.19514Keywords:
Antiviral Agents; Coronavirus; Interferons.Abstract
SARS-CoV-2 virus, cause of COVID-19 disease, was described at first in Wuhan (China) December 2019, infecting more than 170 million people. During viral infection, innate immune system initially acts with cell signaling leading to the production and release of pro-inflammatory cytokines, mostly characterized by low levels of interferons (IFNs), which stimulate the expression of genes that contribute to the displacement of host cells towards an antiviral state. In the SARS-CoV-2, the expression and functions of IFN-I are relatively suppressed. This study aims to evaluate the therapeutic potential of using Interferon in activating the antiviral state, especially in the early stages of the disease. This is an integrative literature review, using an exploratory and descriptive methodology. The data were organized in order to list the studies related to the theme in question, the filtering of the articles found had as inclusion criteria, articles in the years 2020 and 2021 (except for one of them, in the year of 2015), in the languages: Portuguese, English and Spanish. Considering that SARS-CoV-2 suppresses the expression of IFN-I and the genes induced by IFN, interrupting the immune defense mechanisms, there is a relationship of IFN suppression with the worsening of the clinical picture in patients with COVID-19. So that, literature elucidates that the exogenous administration of IFN-I has been shown to reduce the severity of symptoms, however, this mechanism needs to be analyzed more clearly.
References
Bagheri, A., Moezzi, S., Mosaddeghi, P., Nadimi Parashkouhi, S., Fazel Hoseini, S. M., Badakhshan, F., & Negahdaripour, M. (2021). Interferon-inducer antivirals: Potential candidates to combat COVID-19. International immunopharmacology, 91, 107245. https://doi.org/10.1016/j.intimp.2020.107245
Bakadia, B. M., He, F., Souho, T., Lamboni, L., Ullah, M. W., Boni, B. O., Ahmed, A., Mukole, B. M., & Yang, G. (2021). Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 133, 111008. https://doi.org/10.1016/j.biopha.2020.111008
Busnadiego, I., Fernbach, S., Pohl, M. O., Karakus, U., Huber, M., Trkola, A., Stertz, S., & Hale, B. G. (2020). Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. mBio, 11(5), e01928-20. https://doi.org/10.1128/mBio.01928-20
Calabrese, LH, Winthrop, K., Strand, V., Yazdany, J., & Walter, JE (2021). Interferon tipo I, anticorpos anti-interferon e COVID-19. The Lancet Rheumatology , 3 (4), e246-e247.
Chan, J. F., Lau, S. K., To, K. K., Cheng, V. C., Woo, P. C., & Yuen, K. Y. (2015). Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clinical microbiology reviews, 28(2), 465.
Darazam, I. A., Shokouhi, S., Pourhoseingholi, M. A., Irvani, S. S. N., Mokhtari, M., Shabani, M., ... & Khoshkar, A. (2021). Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. Scientific reports, 11(1), 1-11.
Felgenhauer, U., Schoen, A., Gad, H. H., Hartmann, R., Schaubmar, A. R., Failing, K., Drosten, C., & Weber, F. (2020). Inhibition of SARS-CoV-2 by type I and type III interferons. The Journal of biological chemistry, 295(41), 13958–13964. https://doi.org/10.1074/jbc.AC120.013788
Hung, I. F., Lung, K. C., Tso, E. Y., Liu, R., Chung, T. W., Chu, M. Y., Ng, Y. Y., Lo, J., Chan, J., Tam, A. R., Shum, H. P., Chan, V., Wu, A. K., Sin, K. M., Leung, W. S., Law, W. L., Lung, D. C., Sin, S., Yeung, P., Yip, C. C., … Yuen, K. Y. (2020). Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet (London, England), 395(10238), 1695–1704. https://doi.org/10.1016/S0140-6736(20)31042-4
Khamis, F., Al Naabi, H., Al Lawati, A., Ambusaidi, Z., Al Sharji, M., Al Barwani, U., Pandak, N., Al Balushi, Z., Al Bahrani, M., Al Salmi, I., & Al-Zakwani, I. (2021). Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. International journal of infectious diseases : IJID : official publication of the International Society for Infectious
Diseases, 102, 538–543. https://doi.org/10.1016/j.ijid.2020.11.008
Lima, C. M. A. D. O. (2020). Informações sobre o novo coronavírus (COVID-19).
Malekzadeh, R., Murthy, S., Reddy, K. S., Roses Periago, M., Abi Hanna, P., Ader, F., Al-Bader, A. M., Alhasawi, A., Allum, E., Alotaibi, A., … Swaminathan, S. (2021). Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. The New England journal of medicine, 384(6), 497–511. https://doi.org/10.1056/NEJMoa2023184
Mantlo, E., Bukreyeva, N., Maruyama, J., Paessler, S., & Huang, C. (2020). Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral research, 179, 104811. https://doi.org/10.1016/j.antiviral.2020.104811
Medeiros–Pesquisadora, F. C., et al. Interferon Para Profilaxia e Tratamento de Covid-19. Revisão sistemática rápida.
Meffre, E., & Iwasaki, A. (2020). Interferon deficiency can lead to severe COVID.
Monk, P. D., Marsden, R. J., Tear, V. J., Brookes, J., Batten, T. N., Mankowski, M., Gabbay, F. J., Davies, D. E., Holgate, S. T., Ho, L. P., Clark, T., Djukanovic, R., Wilkinson, T., & Inhaled Interferon Beta COVID-19 Study Group (2021). Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Respiratory medicine, 9(2), 196–206. https://doi.org/10.1016/S2213-2600(20)30511-7
Nile, S. H., Nile, A., Qiu, J., Li, L., Jia, X., & Kai, G. (2020). COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine & growth factor reviews, 53, 66–70. https://doi.org/10.1016/j.cytogfr.2020.05.002
Park, A., & Iwasaki, A. (2020). Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19. Cell host & microbe, 27(6), 870–878. https://doi.org/10.1016/j.chom.2020.05.008
Peiffer-Smadja, N., & Yazdanpanah, Y. (2021). Interferon beta-1a nebulizado para pacientes com COVID-19. The Lancet Respiratory Medicine , 9 (2), 122-123.
Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica.
Pumapillo Garcia, A. S., & Quispe Castillo, C. Z. (2021). Esquema de manejo de COVID-19 en adultos. Horizonte Médico (Lima), 21(1).
Pumapillo Garcia, A. S., & Quispe Castillo, C. Z. (2021). Esquema de manejo de COVID-19 en adultos. Horizonte Médico (Lima), 21(1), e1362. https://dx.doi.org/10.24265/horizmed.2021.v21n1.11
Rahmani, H., Davoudi-Monfared, E., Nourian, A., Khalili, H., Hajizadeh, N., Jalalabadi, N. Z., Fazeli, M. R., Ghazaeian, M., & Yekaninejad, M. S. (2020). Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. International immunopharmacology, 88, 106903. https://doi.org/10.1016/j.intimp.2020.106903
Siddiqi, H. K., & Mehra, M. R. (2020). COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal. The journal of heart and lung transplantation, 39(5), 405.
World Health Organization. (2021). Coronavirus disease ( COVID-19): weekly epidemiological update.
Xavier, A. R., Silva, J. S., Almeida, J. P. C., Conceição, J. F. F., Lacerda, G. S., & Kanaan, S. (2020). COVID-19: manifestações clínicas e laboratoriais na infecção pelo novo coronavírus. Jornal Brasileiro de Patologia e Medicina Laboratorial, 56.
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021). The signal pathways and treatment of cytokine storm in COVID-19. Signal transduction and targeted therapy, 6(1), 255. https://doi.org/10.1038/s41392-021-00679-0
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Lucas Mainardo Rodrigues Bezerra; Pedro Oliveira Carvalho Neto; Fernando José de Morais Silva; Madelyne Alice Brito Ramos; Ana Maria Santos Cardoso; Elisiel Martins de Sousa; Moacir Ximenes Sousa Neto; Tássia Layane Pontes Alencar ; Luan Kelves Miranda de Souza
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
